taVNS with ropivacaine block reduces chronic postsurgical pain after off-pump CABG in elderly patients
This randomized controlled trial enrolled 260 elderly patients (≥60 years) undergoing off-pump coronary artery bypass grafting (OPCABG). Participants received either transcutaneous auricular vagus nerve stimulation (taVNS) with a pectoral-intercostal fascial block (PIFB) using ropivacaine, or a sham taVNS with a placebo PIFB.
The primary outcome was the incidence of chronic postsurgical pain (CPSP) at 3 months postoperatively. The overall CPSP incidence was 34.6%. taVNS significantly reduced CPSP incidence compared to sham (28.6% vs 40.9%, p=0.036). PIFB did not significantly reduce overall CPSP incidence compared to placebo (30.2% vs 38.8%, p=0.143). taVNS also alleviated acute pain and improved recovery quality, though specific numbers were not reported. PIFB reduced moderate-to-severe CPSP, but absolute numbers were not reported.
A mediation analysis indicated that taVNS benefits were partially mediated by reducing acute pain (19.3%) and IL-6 levels (20.4%). Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in the abstract.
Key limitations include that the follow-up duration was reported as 720.0 months, which is likely a data entry error, and other limitations were not reported in the abstract. The practice relevance notes that perioperative taVNS significantly reduced CPSP incidence and enhanced postoperative recovery in elderly OPCABG patients, while a single-shot PIFB showed limited preventive effect on overall CPSP.
Given this is a single RCT, certainty may be limited by sample size and follow-up duration. Results should not be overgeneralized to all surgical populations or assumed to have long-term effects beyond 3 months without further data.